• Something wrong with this record ?

Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits

M. Gajdošová, D. Vetchý, J. Muselík, J. Gajdziok, J. Juřica, M. Vetchá, K. Hauptman, V. Jekl

. 2021 ; 592 (-) : 120086. [pub] 20201112

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21019482

The incidence of fungal infections has increased in recent decades not only in patients with predisposing and risk factors, but it has also spread up due to the widespread use of broad-spectrum antibiotics, immunosuppressants and corticosteroids. A limited number of drugs are currently used to treat oral candidiasis (OC). There is an emerging need to look for new antifungals, to rework or to explore the already known molecules. Ciclopirox olamine (CPX), a broad-spectrum antifungal agent, is currently used for topical dermatologic treatment. In this study, bilayer mucoadhesive buccal films (MBFs) containing poly(ethylene oxide) (PEO) and Eudragit® NM 30D (EU) with the prolonged release of ciclopirox olamine, were developed for the treatment of oral candidiasis. During ex vivo testing it was found that CPX does not pass through the porcine buccal tissue but it accumulates in it, which may be beneficial for the treatment of candidiasis in the oral cavity. In a pharmacokinetic study, the drug release from mucoadhesive films was prolonged with the maximum plasma concentration at 3.4 (1.4; 5.5) h. All rabbits with stomatitis showed progressive healing after the treatment with CPX bilayer mucoadhesive buccal films without organ pathologies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019482
003      
CZ-PrNML
005      
20220606093139.0
007      
ta
008      
210728s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2020.120086 $2 doi
035    __
$a (PubMed)33188896
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Gajdošová, Markéta $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 62500 Brno, Czech Republic
245    10
$a Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits / $c M. Gajdošová, D. Vetchý, J. Muselík, J. Gajdziok, J. Juřica, M. Vetchá, K. Hauptman, V. Jekl
520    9_
$a The incidence of fungal infections has increased in recent decades not only in patients with predisposing and risk factors, but it has also spread up due to the widespread use of broad-spectrum antibiotics, immunosuppressants and corticosteroids. A limited number of drugs are currently used to treat oral candidiasis (OC). There is an emerging need to look for new antifungals, to rework or to explore the already known molecules. Ciclopirox olamine (CPX), a broad-spectrum antifungal agent, is currently used for topical dermatologic treatment. In this study, bilayer mucoadhesive buccal films (MBFs) containing poly(ethylene oxide) (PEO) and Eudragit® NM 30D (EU) with the prolonged release of ciclopirox olamine, were developed for the treatment of oral candidiasis. During ex vivo testing it was found that CPX does not pass through the porcine buccal tissue but it accumulates in it, which may be beneficial for the treatment of candidiasis in the oral cavity. In a pharmacokinetic study, the drug release from mucoadhesive films was prolonged with the maximum plasma concentration at 3.4 (1.4; 5.5) h. All rabbits with stomatitis showed progressive healing after the treatment with CPX bilayer mucoadhesive buccal films without organ pathologies.
650    _2
$a aplikace bukální $7 D000278
650    _2
$a zvířata $7 D000818
650    _2
$a antifungální látky $x metabolismus $7 D000935
650    12
$a orální kandidóza $x farmakoterapie $x metabolismus $7 D002180
650    _2
$a ciklopirox $x terapeutické užití $7 D000077768
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a lidé $7 D006801
650    _2
$a ústní sliznice $x metabolismus $7 D009061
650    _2
$a králíci $7 D011817
650    _2
$a prasata $7 D013552
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vetchý, David $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 62500 Brno, Czech Republic. Electronic address: vetchy@email.cz
700    1_
$a Muselík, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 62500 Brno, Czech Republic
700    1_
$a Gajdziok, Jan $u Department of Pharmaceutical Technology, Faculty of Pharmacy, Masaryk University, 62500 Brno, Czech Republic
700    1_
$a Juřica, Jan $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic
700    1_
$a Vetchá, Martina $u GSK, s r.o., Prague, Czech Republic $7 xx0273605
700    1_
$a Hauptman, Karel $u Veterinary Clinic Jekl & Hauptman, 61200 Brno, Czech Republic
700    1_
$a Jekl, Vladimír $u Veterinary Clinic Jekl & Hauptman, 61200 Brno, Czech Republic; The Avian and Exotic Animal Clinic, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, 61242 Brno, Czech Republic
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 592, č. - (2021), s. 120086
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33188896 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20220606093137 $b ABA008
999    __
$a ok $b bmc $g 1690329 $s 1139928
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 592 $c - $d 120086 $e 20201112 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options